Amanda M Brandow, DO
Accepting new patients
Dr. Brandow is a board certified pediatric hematologist/oncologist. She has a special interest in providing comprehensive and compassionate care for children with sickle cell disease and other hemoglobinopathies in addition to other hematologic diseases including children with anemia, thrombocytopenia and neutropenia. Dr. Brandow is specifically interested in developing better ways to assess and treat pain in children with sickle cell disease. She is committed to and enjoys teaching medical students, residents, and fellows to help them learn to provide comprehensive and compassionate care to their patients.
- Pediatric Hematology-Oncology, Pediatrics
Areas of Interest
- Sickle cell disease
- BMT for sickle cell disease
- Sickle cell disease neuropsychological complications
- Sickle cell disease new therapeutic agents
Education and Awards
- 2008, Medical College of Wisconsin, MS
- 2001, Midwestern University (Downers Grove, IL), DO
2004, Medical College of Wisconsin - Pediatrics2005, Medical College of Wisconsin - Pediatrics
2008, Medical College of Wisconsin - Ped Hem/Onc
- Milwaukee Top Doctors 2013
- Outstanding Medical Student Teacher (Medical College of Wisconsin) 2011, 2012
- Best Doctors in America
Research and publications
Dr. Brandow’s research is focused on investigating the underlying reasons that children with sickle cell disease experience pain. She is also interested in studying chemotherapy associated pain in children with cancer. Through this research she hopes to develop new pain treatments for both children with sickle cell disease and cancer. Dr. Brandow also studies ways to better assess pain in children with sickle cell disease and cancer and the outcomes of pain treatment in these children.
- Patients with sickle cell disease have increased sensitivity to cold and heat.
- Neuropathic pain in patients with sickle cell disease.
- The impact of a multidisciplinary pain management model on sickle cell disease pain hospitalizations.
- TRPV1 mediates pain in mice with severe sickle cell disease.
- Post-discharge pain, functional limitations, and caregiver impact after children with sickle cell disease seek treatment for vaso-occlusive painful events.
- Peripheral Sensitization as a Novel Mechanism for Pain in Sickle Cell Disease
NIH Loan Repayment Program in Pediatric Research
- Quantitative Assessment of Neuropathic Pain in Pediatric Oncology Patients Treated with Vincristine
Midwest Athletes Against Childhood Cancer (MACC Fund)
- Pharmacokinetics and Relative Bioavailability of a Liquid Formulation of Hydroxyurea in Pediatric Patients with Sickle Cell Anemia
NIH/NICHD; NIH subcontract
Site Principal Investigator